About Us

Functional Fluidics

Why We Do What We Do

Millions of people around the world are affected by Sickle Cell Disease (SCD), but qualitative biomarkers to objectively monitor red blood cell health are lacking.

Individuals with Sickle Cell Disease may experience a range of complications, including debilitating pain crises. While certain treatments and lifestyle changes may help, without qualitative biomarkers, patients, providers, and pharmaceutical companies are not empowered to make the necessary advancements in Sickle Cell Disease care.

As an ICU Physician, Functional Fluidics’ CEO & Founder, Patrick Hines, has treated patients with serious health conditions resulting from abnormal red blood cell function. He also felt the frustration of not having the right diagnostic tools to predict problems, treat illness, and monitor the response of therapies in patients. It became his life mission to develop the diagnostic tools so that people in need can receive the right care.

Functional Fluidics is a fulfillment of that mission: The Gold Standard in Red Blood Cell Health.


What Does This Mean For You?

  •  
    Better Decisions about drug development & patient care
  •  
    Unique diagnostic platforms that assess the health of red blood cells
  •  
    A successful research strategy to facilitate clinical studies/trials
  •  
    Access to well- validated biomarkers
  •  
    Ability to objectively assess the impact on red blood cell health, and ultimately patient health

SOLUTIONS FOR OUR PARTNERS

abc
 

Clinical Providers

Diagnosis and ongoing patient monitoring as a clinical tool

LEARN MORE
new04
 

Pharma

Contract Research Services leveraging our proprietary biomarker assays to support the advancement of red blood cell therapies.

LEARN MORE
new03
 

Insurance Payers

Improving patient lives while reducing the inefficiencies and costs across the healthcare network.

LEARN MORE
003-1
 

Investor Relations

As we continue our growth, we invite those interested in investing our expansion to engage with our team

LEARN MORE
 

Why Choose Functional Fluidics?

  • New Project

    Proprietary Lab Tests

  • New Project(1)

    CLIA Certified Lab

  • New Project(5)

    Complex Tests Experience

  • New Project(2)

    Thought Leader Access

  • New Project(3)

    Specialized Staff

  • New Project(4)

    Strong Industry Relationships



Functional Fluidics Assays

Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.

  • 10    
    Flow Adhesion of whole blood on VCAM-1 (FA-WB-VCAM)
    LEARN MORE
  • 11    
    Flow Adhesion of whole blood on P-Selectin (FA-WB-Psel)
    LEARN MORE
  • 12    
    Mechanical Fragility – Normoxia (MF)
    LEARN MORE
 

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)

13
 
    

Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.

Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.

LEARN MORE
04-1    

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

Functional Fluidics Biomarker  Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine

Key Points

  • Feasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.
  • ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.
LEARN MORE
14    
 

Publications

FLOW ADHESION

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

This non interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

MECHANICAL FRAGILITY

Red Blood Cell Mechanical Fragility as Potential Metric for Assessing Blood Damage Caused by Implantable Durable Ventricular Assist Devices: Comparison of Two Types of Centrifugal Flow Left Ventricular Assist Devices.

Implantable Ventricular Assist Devices (VADs) have become a treatment of choice for patients with end-stage heart failure or cardiogenic shock, significantly increasing both survival rates and the quality of life of patients.

MECHANICAL FRAGILITY

Individual Variability in Response to a Single Sickling Event for Normal, Sickle Cell, and Sickle Trait Erythrocytes

Hemoglobin S (Hb-S) polymerization is the primary event in sickle cell disease causing irreversible damage to red blood cell (RBC) membranes over repeated polymerization cycles.

FLOW ADHESION

Sevuparin blocks sickle blood cell adhesion and sickleleucocyte rolling on immobilized L-selectin in a dose dependent manner

Adhesion of sickle red blood cells (SSRBC) to the vascular endothelium may initiate and propagate vascular obstruction in sickle cell disease (SCD)

MECHANICAL FRAGILITY

Impact of Environment on Red Blood Cell ability to Withstand Mechanical Stress.

Susceptibility of red blood cells (RBC) to hemolysis under mechanical stress is represented by RBC mechanical fragility (MF), with different types or intensities of stress potentially emphasizing different perturbations of RBC membranes

MECHANICAL FRAGILITY

An Approach to Measuring RBC Haemolysis and Profiling RBC Mechanical Fragility

Red blood cells (RBC) can be damaged by medical products, from storage or from disease. Haemolysis (cell rupture and haemoglobin release) is often a key indicator, with mechanical fragility (MF) offering the potential to assess sub-haemolytic damage as well

FLOW ADHESION

Low Molecular Weight Heparin Inhibits Sickle Erythrocyte Adhesion to VCAM-1 through VLA-4 Blockade in a Standardized Microfluidic Flow Adhesion Assay

The vaso-occlusive events in sickle cell disease (SCD) begin in early childhood, warranting the need for more preventative and therapeutic interventions for those affected

MECHANICAL FRAGILITY

Impact of the Oscillating Bead Size and Shape on Induced Mechanical Stress on Red Blood Cells and Associated Hemolysis in Bead Milling

While in circulation, red blood cells (RBC) need to elastically undergo large deformations without lysing, an ability that may be compromised by cell membrane damage.